Aims & Scope
Human Antibodies is an international journal designed to bring together all aspects of human hybridomas and antibody technology under a single, cohesive theme.
This includes fundamental research, applied science and clinical applications.
Emphasis in the published articles is on antisera, monoclonal antibodies, fusion partners, EBV transformation, transfections, in vitro immunization, defined antigens, tissue reactivity, scale-up production, chimeric antibodies, autoimmunity, natural antibodies/immune response, anti-idiotypes, and hybridomas secreting interesting growth factors.
Immunoregulatory molecules, including T cell hybridomas, will also be featured.
View Aims & ScopeMetrics & Ranking
SJR (SCImago Journal Rank)
Year | Value |
---|---|
2024 | 0.499 |
Quartile
Year | Value |
---|---|
2024 | Q3 |
h-index
Year | Value |
---|---|
2024 | 29 |
Journal Rank
Year | Value |
---|---|
2024 | 11619 |
Journal Citation Indicator
Year | Value |
---|---|
2024 | 96 |
Abstracting & Indexing
Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.
Subjects & Keywords
Journal’s research areas, covering key disciplines and specialized sub-topics in Immunology and Microbiology and Medicine, designed to support cutting-edge academic discovery.
Most Cited Articles
The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.
-
Antibody polyspecificity and neutralization of HIV-1: A hypothesis
Citation: 131
Authors: Barton F., M. Anthony, Laurent, Garnett, S. Munir
-
Global burden of COVID-19: Situational analyis and review
Citation: 114
Authors: Addis Adera, Tadesse, Eshetu, Agumas Fentahun, Selamawit, Hussen Zakir, Ali, Bosenu Abera, Beniam Adera, Berhanu Senbeta, Nigus Shimelis, Abebe Gule, Bulgantsetseg, Qamar Kassim, Amana Ogeto, Dejene
-
Humanization of a mouse antibody against human alpha-4 integrin: A potential therapeutic for the treatment of multiple sclerosis
Citation: 105
Authors: Olivier J.P., Ted A., Laura, Heidi C., Dawn K., Simon, José, S. Tarran, Lawrence C., Mary M.
-
Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma
Citation: 98
Authors: Mansoor N., M.B., Richard H., Laquetta, Arabella B., William, Ralph A., Alice L., Stephen D., Albert F.
-
In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody
Citation: 73
Authors: Richard A., Benita K., Avinash, Christopher M., Carlos A., Mark D.
-
The biological activity of human monoclonal IgG anti-D is reduced by β-galactosidase treatment
Citation: 66
Authors: Belinda M., Yan, Helen L., Andrew G., Graham A.W.
-
IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab
Citation: 65
Authors: Dipa, Xuemei, Stanley, Maxine, Paul, Douglas, Kris, Xenia, Dale L., Xiaoqiang
-
Nanobodies: The “Magic Bullets†in therapeutics, drug delivery and diagnostics
Citation: 62
Authors: Manzoor A., Umar, Bashir Ahmad, Syed Suhail
-
Efficient in vitro affinity maturation of phage antibodies using BIAcore guided selections
Citation: 61
Authors: Robert, James D.
-
Tumor angiogenesis and anti-angiogenic therapies
Citation: 60
Authors: Fatemeh Zare, Behzad, Fatemeh, Leili